Download Files

Learn What Lies Ahead for the HHS, the FDA, and Medicaid and Medicare under the New HHS-Secretary, Alex Azar

President Trump confirmed Alex Azar to be the new Health and Human Services (HHS) secretary, which will have an important impact on HHS in general and the FDA in particular. Join this session, where regulatory expert Norma Skolnik will explore the implications of Alex being the new secretary of the HHS. This session will provide a background on Alex, President Trump’s new Head of the Department of HHS.

The session will further cover the likely trends that may be expected under Alex’s administration based on his background and statements made at his confirmation hearing. Norma will explore Alex’s potential impact on the future of the FDA, drug and device regulations, drug pricing, and the drug approval process. She will also discuss Alex’s attitude toward Medicaid and Medicare. You will get references to all relevant regulations and documentation.

Session Highlights

Alex Azar’s history and background, and statements made during his confirmation hearing

President Trump’s stated intentions to address drug pricing and where Alex stands on the issue

Past policies that HHS-head, Alex, has supported, as well as his likely intentions for HHS programs

Key issues facing HHS that Alex is likely to address, such as the Affordable Care Act, drug pricing, patent protection and generic drugs

Potential actions Alex supports regarding Medicaid and Medicare

Who Should Attend

Regulatory affairs managers

Directors and associates

Drug-safety managers

Compliance specialists

Drug and device managers

Marketing managers and anyone involved in marketing prescription drugs, biologics and OTC drugs, medical devices, or supplements in the U.S.

Medicare and Medicaid administrators

Ask a question at the Q&A session following the live event and get advice unique to your situation, directly from our expert speaker.

Norma Skolnik has over 35 years of regulatory experience working with the pharmaceutical and dietary supplement industries. She served as Director of Regulatory Affairs for the Americas for Cadbury Adams. Prior to that, she was Director of Regulatory Affairs for the Adams Division of Pfizer and Associate Director of Regulatory Affairs for the Warner-Lambert company. She also served as Director of Regulatory Affairs for Lederle Consumer Healthcare and...
More InfoMore Events By The Speaker